The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours.
SpringWorks Therapeutics Announces Dosing Of First Patient In Phase 1b/2 Trial Evaluating Nirogacestat In Combination With Elranatamab In Patients With Relapsed Or Refractory Multiple Myeloma
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first
SpringWorks Therapeutics Enters Exclusive Worldwide License Agreement With Dana-Farber Cancer Institute And Sponsored Research Agreement With Stanford Medicine
Portfolio is Currently in Lead Optimization and Includes Several Novel Approaches for Targeting Mutant EGFR that are Designed to Address Both De Novo Oncogenic Drivers and Emerging Resistance Mutations -
- Chemistry
JP Morgan Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $105
JP Morgan analyst Anupam Rama maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target from $97 to $105.
SpringWorks Therapeutics Enters Research Collaboration With Dana-Farber Cancer Institute To Further Evaluate Nirogacestat As A BCMA Potentiator In Multiple Myeloma; Under Terms, Co. To Be Responsible For Funding Work
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has
HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $137
HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the price target from $136 to $137.
SpringWorks Therapeutics Q2 EPS $(0.97) Down From $(0.47) YoY
SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(0.97) per share. This is a 106.38 percent decrease over losses of $(0.47) per share from the same period last year.
HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $136
HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the price target from $124 to $136.
SpringWorks Therapeutics Highlights Issuance Of New US Composition Of Matter Patent To Polymorphic Form Of Mirdametinib, Extends Patent Protection Into 2041
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,066,358 (the ‘358 patent), directed to mirdametinib, the
Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial
Precision BioSciences Inc (NASDAQ:DTIL) and SpringWorks Therapeutics Inc (NASDAQ:SWTX) have dosed the first patient in the combination arm of Precision’s Phase 1/2a trial…